---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-004486"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:32:35.086523+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health signs non-binding LOI to merge with Speranza Therapeutics in all-stock deal

## Summary
- Speranza's lead product ST Genesis is a wearable device for opioid withdrawal, FDA cleared, 93% response rate, targets $1.4B market.
- Transaction makes Speranza a wholly owned subsidiary of Odyssey; Speranza management to remain post-closing.
- Merger subject to due diligence, financing, and other conditions; deal terms were not disclosed.

## SEC filing metadata
- accession: 0001683168-23-004486
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316823004486/0001683168-23-004486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316823004486/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-004486
- JSON: https://secwatch.observer/filing/0001683168-23-004486.json
- Plain text: https://secwatch.observer/filing/0001683168-23-004486.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.